---
schema_version: "secwatch.filing_event.v1"
accession: "0000313143-25-000006"
form_type: "8-K"
ticker: "HAE"
cik: "0000313143"
company_name: "HAEMONETICS CORP"
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T02:26:38.262470+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Haemonetics completes sale of whole blood assets to GVS for up to $67.8M

## Summary
- Total cash consideration up to $67.8M: $45.3M upfront (adjusted) plus up to $22.5M contingent.
- Contingent consideration tied to three-year sales growth and other milestones.
- Transaction closed on January 13, 2025, as previously disclosed in December 2024 8-K.
- Assets divested are within the Blood Center business unit's whole blood segment.

## SEC filing metadata
- accession: 0000313143-25-000006
- form_type: 8-K
- ticker: HAE
- cik: 0000313143
- company_name: HAEMONETICS CORP
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/313143/000031314325000006/0000313143-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/313143/000031314325000006/hae-20250114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000313143-25-000006
- JSON: https://secwatch.observer/filing/0000313143-25-000006.json
- Plain text: https://secwatch.observer/filing/0000313143-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.